Seasoned operator-turned-investor active in growth-stage technology and software markets, Nicholas McElroy brings operating, fundraising and board-level experience to venture and private equity engagements. Focuses on scaling SaaS, fintech and digital marketplace businesses, advising management teams on go-to-market, product-market fit and capital strategy. Known for hands-on portfolio involvement, capital allocation discipline and bridging founders to institutional LPs and strategic acquirers.
Seasoned operator-turned-investor active in growth-stage technology and software markets, Nicholas McElroy brings operating, fundraising and board-level experience to venture and private equity engagements. Focuses on scaling SaaS, fintech and digital marketplace businesses, advising management teams on go-to-market, product-market fit and capital strategy. Known for hands-on portfolio involvement, capital allocation discipline and bridging founders to institutional LPs and strategic acquirers.
Operator-led growth investor who prioritizes scalable SaaS, fintech and digital marketplace opportunities, deploying capital at Series A–C with a bias toward value creation over short-term exits. Applies hands-on operating playbooks to accelerate go-to-market, product–market fit and unit economics while preserving disciplined portfolio construction and capital allocation. Seeks founder-aligned governance, measurable KPIs, and strategic paths to institutional follow-on funding or acquisition, leveraging board experience and LP/acquirer networks.
Operator-led growth investor who prioritizes scalable SaaS, fintech and digital marketplace opportunities, deploying capital at Series A–C with a bias toward value creation over short-term exits. Applies hands-on operating playbooks to accelerate go-to-market, product–market fit and unit economics while preserving disciplined portfolio construction and capital allocation. Seeks founder-aligned governance, measurable KPIs, and strategic paths to institutional follow-on funding or acquisition, leveraging board experience and LP/acquirer networks.
| Trades 1462 | Longs Won 1017/1462 69% | Profit Factor 7.76 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.61M |
| Average Win $276,702.91 | Best Trade (Jun 30) $50.93M | Sharpe Ratio -3.31 |
| Average Loss -$81,517.41 | Worst Trade (Sep 30) -$3.66M | Z-Score 6.45 (100%) |
| Commissions $0 | Avg. Trade Length 1y 1m 2w 1d | Expectancy $167,668.68 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 11,628 | 10,465 | 9,302 | 8,140 | 6,977 | 5,814 | 4,651 | 3,488 | 2,326 | 1,163 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 7840 78409V112 | 736 | $299,878 | $299,878 | - | - | - | 0.0 |
AAPL Apple Inc. | 19,082 | $4.28M | $5.89M | - | $1.62M | 37.77% | -7.354% |
ABT Abbott Laboratories | 281,731 | $25.66M | $29.78M | - | $4.12M | 16.04% | +0.085% |
ACWX ISHARES MSCI ACWI EX U.S. ETF | 37,648 | $2.02M | $2.83M | - | $810,507.82 | 40.07% | -0.172% |
AGG iShares Core U.S. Aggregate Bond ETF | 3,603 | $349,130.32 | $350,824.11 | - | $1,693.79 | 0.49% | -0.256% |
ALLY Ally Financial Inc. | 109,742 | $3.91M | $4.76M | - | $849,406.57 | 21.75% | -0.345% |
AMGN Amgen Inc. | 8,948 | $2.88M | $3.45M | - | $563,194.06 | 19.53% | -0.64% |
AMZN Amazon.com Inc | 6,856 | $1.15M | $1.86M | - | $713,626.42 | 62.14% | +15.321% |
AOR iShares Core 60/40 Balanced Allocation ETF | 3,071 | $213,439 | $210,455.63 | - | -$2,983.37 | -1.4% | +0.058% |
APA APA Corporation | 6,741 | $164,012.66 | $251,574.12 | - | $87,561.46 | 53.39% | +2.725% |
AVEM Avantis Emerging Markets Equity ETF | 32,753 | $2.28M | $2.93M | - | $655,036.45 | 28.77% | +0.101% |
AXP American Express Company | 2,109 | $572,259.28 | $709,151.25 | - | $136,891.97 | 23.92% | -0.376% |
BABA Alibaba Group Holding Limited SP ADR | 27,566 | $2.93M | $3.37M | - | $444,639.56 | 15.2% | +5.098% |
BAC Bank of America Corporation | 128,412 | $5.1M | $7.96M | - | $2.86M | 56.12% | +0.356% |
BF-B Brown-Forman Corporation | 259,241 | $7.02M | $7.45M | - | $424,067.34 | 6.04% | -0.347% |
BIIB Biogen Inc. | 1,702 | $244,952.03 | $345,420.9 | - | $100,468.87 | 41.02% | -2.395% |
BMRN Biomarin Pharmaceutical Inc. | 6,494 | $371,587 | $389,769.88 | - | $18,182.88 | 4.89% | -0.924% |
BRK-A Berkshire Hathaway Inc. | 3 | $2.4M | $2.3M | - | -$95,525 | -3.99% | +0.21% |
BRK-B Berkshire Hathaway Inc. | 434,980 | $200.2M | $222.51M | - | $22.31M | 11.14% | +0.365% |
BTI British American Tobacco p.l.c. ADR | 127,523 | $4.67M | $7.73M | - | $3.06M | 65.54% | -1.686% |